Vasoprotective and Atheroprotective Effects of Angiotensin (1-7) in Apolipoprotein E–Deficient Mice
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Objective—To evaluate the effectiveness of long-term angiotensin (Ang) (1-7) treatment to inhibit the progression of atherosclerosis in apolipoprotein E-deficient (ApoE−/−) mice. Methods and Results—Ang (1-7) is a heptapeptide fragment that has been proposed to counterregulate the Ang II proatherogenic effects. The effect of long-term 4-week Ang (1-7) treatment on both inhibition of atherosclerotic lesion development and improvement of endothelial function was examined in apolipoprotein E−/−mice that had been fed an atherogenic high-fat (21%) diet for 16 weeks. Chronic Ang (1-7) treatment significantly improved endothelial function, an effect reversed with either angiotensin type 2 (AT 2) or Mas receptor blockade. In these vessels, Ang (1-7) treatment significantly decreased superoxide production and increased endothelial nitric oxide synthase immunoreactivity when compared with vehicle treatment. These effects were blocked by both AT 2 and Mas receptor antagonists. Lesion development, assessed as both fatty deposits (oil red O) and intima to media ratio, was also significantly decreased with Ang (1-7) treatment compared with respective controls. Cotreatment with either AT 2 or Mas receptor antagonists reversed Ang (1-7)–mediated reduction in lesion development. Conclusion—Long-term Ang (1-7) treatment caused both vasoprotection, via improvement in endothelial function, and atheroprotection, with a reduction in lesion progression in a model of atherosclerosis. These effects appear to be mediated by the restoration of nitric oxide bioavailability and involve a complex interaction of both Mas and AT 2 receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tsutsumi, Y., Matsubara, H., Ohkubo, N., Mori, Y., Nozawa, Y., Murasawa, S., Kijima, K., Maruyama, K., Masaki, H., Moriguchi, Y., et al. (1998) · Circulation Research · doi:10.1161/01.res.83.10.1035 · Cited by 241
Cited by
Tikellis, C., & Thomas, M. C. (2012) · International Journal of Peptides · doi:10.1155/2012/256294 · Cited by 624
Counter-regulatory renin–angiotensin system in cardiovascular disease
Paz Ocaranza, M., Riquelme, J. A., García, L., Jalil, J. E., Chiong, M., Santos, R. A. S., & Lavandero, S. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0244-8 · Cited by 561
Cheng, H., Wang, Y., & Wang, G. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25785 · Cited by 548
Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets
Jiang, F., Yang, J., Zhang, Y., Dong, M., Wang, S., Zhang, Q., Liu, F. F., Zhang, K., & Zhang, C. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.59 · Cited by 426
Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors
Bosnyak, S., Jones, E. S., Christopoulos, A., Aguilar, M.-I., Thomas, W. G., & Widdop, R. E. (2011) · Clinical Science · doi:10.1042/cs20110036 · Cited by 288
Self-citationSantos, R. A. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.01274 · Cited by 259
Thomas, M. C., Pickering, R. J., Tsorotes, D., Koitka, A., Sheehy, K., Bernardi, S., Toffoli, B., Nguyen-Huu, T.-P., Head, G. A., Fu, Y., et al. (2010) · Circulation Research · doi:10.1161/circresaha.110.219279 · Cited by 232
ACE2–angiotensin-(1–7)–Mas axis and oxidative stress in cardiovascular disease
Rabelo, L. A., Alenina, N., & Bader, M. (2011) · Hypertension Research · doi:10.1038/hr.2010.235 · Cited by 171
Renin-Angiotensin System in Pathogenesis of Atherosclerosis and Treatment of CVD
Poznyak, A. V., Bharadwaj, D., Prasad, G., Grechko, A. V., Sazonova, M. A., & Orekhov, A. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136702 · Cited by 142
“Ang-1–7 was also observed to suppress the VSMCs migration and proliferation unlike the Ang-II-induced proliferative and hypertrophic effects [58].”
BackgroundThe Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target
Steckelings, U. M., Widdop, R. E., Sturrock, E. D., Lubbe, L., Hussain, T., Kaschina, E., Unger, T., Hallberg, A., Carey, R. M., & Sumners, C. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000281 · Cited by 97
Self-citationFavorable Vascular Actions of Angiotensin-(1–7) in Human Obesity
Schinzari, F., Tesauro, M., Veneziani, A., Mores, N., Di Daniele, N., & Cardillo, C. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10280 · Cited by 57
“Previous studies have suggested a role for Ang-(1–7) to improve endothelial function in normotensive(36) and high-salt diet–fed(37) rats, as well as in apolipoproteindeficient mice.(38) Similarly, ACE2 overexpression(15) or activation(39) promotes beneficial effects on endothelial function”
BackgroundTikellis, C., Pickering, R., Tsorotes, D., Du, X.-J., Kiriazis, H., Nguyen-Huu, T.-P., Head, G. A., Cooper, M. E., & Thomas, M. C. (2012) · Clinical Science · doi:10.1042/cs20110668 · Cited by 57
20-Hydroxyecdysone activates the protective arm of the renin angiotensin system via Mas receptor
Lafont, R., Raynal, S., Serova, M., Didry-Barca, B., Guibout, L., Latil, M., Dilda, P. J., Dioh, W., & Veillet, S. (2020) · doi:10.1101/2020.04.08.032607 · Cited by 11
Metadata
- Authors
- Tesanovic, S., Vinh, A., Gaspari, T. A., Casley, D., & Widdop, R. E.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2010-08
- Volume
- 30
- Issue
- 8
- Pages
- 1606-1613
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2137329488
- Cited by
- 151
- References
- 1
- FWCI
- 11.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.